Gossamer Bio, Inc.
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Resolved
134days ago
Phase 2 readout Β· Feb 23, 2026
What's at stake
Phase 2 trial results for seralutinib in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) are due Feb 23, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
Β· SEC 8-K
verified 15h ago
βResults in Overall Patient Population 6 While Separation from Placebo is Apparent, Seralutinib Did Not Meet the Primary Endpoint of Ξ in 6MWD at Week 24 (Ξ± = 0.025)β